Millendo Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLND research report →
Companywww.millendo.com
Millendo Therapeutics, Inc. , a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women.
- CEO
- Julia Owens
- IPO
- 2012
- Employees
- 12
- HQ
- Ann Arbor, MI, US
Price Chart
Valuation
- Market Cap
- $11.15M
- P/E
- -0.27
- P/S
- 0.00
- P/B
- 14.10
- EV/EBITDA
- -1.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -729.89%
- ROIC
- -319.49%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,262,000 · 37.24%
- EPS
- $-6.33 · -322.00%
- Op Income
- $0
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $41.55
- 52W Low
- $1.06
- 50D MA
- $18.86
- 200D MA
- $25.14
- Beta
- 0.48
- Avg Volume
- 140.97K
Get TickerSpark's AI analysis on MLND
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 20 | Nuechterlein Carole | other | 12,000 |
| Jun 22, 20 | HOWE JOHN P MD | other | 12,000 |
| Jun 22, 20 | Gallagher Carol Giltner | other | 12,000 |
| Jun 22, 20 | NICHOL GEOFFREY | other | 12,000 |
| Jun 22, 20 | Hindman James M. | other | 12,000 |
| May 25, 20 | JOSEPH TAMARA L | other | 80,000 |
| May 25, 20 | Arbet-Engels Christophe | other | 80,000 |
| Feb 10, 20 | Arbet-Engels Christophe | other | 140,000 |
| Feb 10, 20 | Arbet-Engels Christophe | other | 0 |
| Jan 31, 20 | JOSEPH TAMARA L | other | 56,250 |
Our MLND Coverage
We haven't published any research on MLND yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MLND Report →